首页-
Products -
Others -
Other Targets -
2-{2-[(5-cyclopropyl-4-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl]propanamido}-4H,5H,6H-cyclopenta[b]thiophene-3-carboxamide
2-{2-[(5-cyclopropyl-4-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl]propanamido}-4H,5H,6H-cyclopenta[b]thiophene-3-carboxamide
CAS No. 920868-45-7
2-{2-[(5-cyclopropyl-4-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl]propanamido}-4H,5H,6H-cyclopenta[b]thiophene-3-carboxamide ( —— )
产品货号. M28453 CAS No. 920868-45-7
2-{2-[(5-cyclopropyl-4-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl]propanamido}-4H,5H,6H-cyclopenta[b]thiophene-3-carboxamide is a compound used as a molecular building block.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥867 | 有现货 |
|
5MG | ¥1482 | 有现货 |
|
10MG | ¥2406 | 有现货 |
|
25MG | ¥3985 | 有现货 |
|
50MG | ¥5816 | 有现货 |
|
100MG | ¥7995 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称2-{2-[(5-cyclopropyl-4-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl]propanamido}-4H,5H,6H-cyclopenta[b]thiophene-3-carboxamide
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述2-{2-[(5-cyclopropyl-4-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl]propanamido}-4H,5H,6H-cyclopenta[b]thiophene-3-carboxamide is a compound used as a molecular building block.
-
产品描述2-{2-[(5-cyclopropyl-4-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl]propanamido}-4H,5H,6H-cyclopenta[b]thiophene-3-carboxamide is a compound used as a molecular building block.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体PPARα;PPARγ;PPARδ
-
研究领域——
-
适应症——
化学信息
-
CAS Number920868-45-7
-
分子量453.6
-
分子式C22H23N5O2S2
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCC(Sc1nnc(C2CC2)n1-c1ccccc1)C(=O)Nc1sc2CCCc2c1C(N)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
Methyl nomilinate
Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.
-
2-Furoyl-LIGRLO-amid...
2-Furoyl-LIGRLO-amide is a potent and selective protease-activated receptor 2 (PAR2) agonist.
-
AM966
AM966, a excellent affinity, specific, oral LPA1(IC50=17 nM) antagonist, suppresses LPA-stimulated intracellular calcium release.